Role of the methoxy group in immune responses to mpeg-protein conjugates

Bioconjugate Chemistry

Volumn 23, Issue 3, 2012, Pages 485-499

  Sherman, Merry R ^a   Williams, L David ^a   Sobczyk, Monika A ^a   Michaels, Shawnya J ^a   Saifer, Mark G P ^a  

^a Mountain View Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; ASSAYS; CHEMICAL DETECTION; ENZYMES; GLYCOPROTEINS; IMMUNE SYSTEM; IMMUNIZATION; LIPOSOMES;

CONJUGATED LIPOSOMES; CONJUGATED PROTEINS; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH AFFINITY; IMMUNE RESPONSE; METHOXY GROUP; PROTEIN CONJUGATES; SUPER OXIDE DISMUTASE; SUPEROXIDE DISMUTASES; URICASE;

ANTIBODIES;

ALPHA INTERFERON; HUMAN SERUM ALBUMIN; HYDROXYPOLYETHYLENE GLYCOL; IMMUNOLOGICAL ADJUVANT; MACROGOL DERIVATIVE; METHOXYPOLYETHYLENE GLYCOL; POLYCLONAL ANTIBODY; POLYSORBATE 20; POLYSORBATE 80; SUPEROXIDE DISMUTASE; TERT BUTOXYPOLYETHYLENE GLYCOL; UNCLASSIFIED DRUG; URATE OXIDASE;

ANIMAL EXPERIMENT; ANTIBODY AFFINITY; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BINDING AFFINITY; CONJUGATE; DRUG CONJUGATION; DRUG STRUCTURE; DRUG SYNTHESIS; EMULSION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; RABBIT; SENSITIVITY AND SPECIFICITY;

ORYCTOLAGUS CUNICULUS; SUS;

EID: 84858710067     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc200551b     Document Type: Article

References (54)

1. Abuchowski, A., van Es, T., Palczuk, N. C., and Davis, F. F. (1977) Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol J. Biol. Chem. 252, 3578-3581 (Pubitemid 8116087)
2. Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T., and Davis, F. F. (1977) Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase J. Biol. Chem. 252, 3582-3586 (Pubitemid 8116088)
3. Lee, W. Y. and Sehon, A. H. (1978) Suppression of reaginic antibodies with modified allergens. I. Reduction in allergenicity of protein allergens by conjugation to polyethylene glycol Int. Arch. Allergy Appl. Immunol. 56, 159-170 (Pubitemid 8261232)
4. Richter, A. W. and Åkerblom, E. (1983) Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins Int. Arch. Allergy Appl. Immunol. 70, 124-131 (Pubitemid 13171427)
5. Richter, A. W. and Åkerblom, E. (1984) Polyethylene glycol reactive antibodies in man: Titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors Int. Arch. Allergy Appl. Immunol. 74, 36-39 (Pubitemid 14136479)
6. Armstrong, J. K. (2009) The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol). In PEGylated Protein Drugs: Basic Science and Clinical Applications (Veronese, F. M., Ed.) pp 147-168, Birkhäuser Verlag, Basel, Switzerland.
7. Su, Y.-C., Chen, B.-M., Chuang, K.-H., Cheng, T.-L., and Roffler, S. R. (2010) Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies Bioconjugate Chem. 21, 1264-1270
8. Fishburn, C. S. (2008) The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics J. Pharm. Sci. 97, 4167-4183
9. Alconcel, S. N. S., Baas, A. S., and Maynard, H. D. (2011) FDA-approved poly(ethylene glycol)-protein conjugate drugs Polym. Chem. 2, 1442-1448
10. Duncan, R. (2011) Polymer therapeutics as nanomedicines: New perspectives Curr. Opin. Biotechnol. 22, 492-501
11. Ng, E. W. and Adamis, A. P. (2006) Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases Ann. N.Y. Acad. Sci. 1082, 151-171 (Pubitemid 44955460)
12. Immordino, M. L., Dosio, F., and Cattel, L. (2006) Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential Int. J. Nanomedicine 1, 297-315
13. Martinez, A. L., Sherman, M. R., Saifer, M. G. P., and Williams, L. D., Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof. U.S. Patent No. 8,129,330 B1, March 6, 2012.
14. Sherman, M. R., Saifer, M. G. P., and Perez-Ruiz, F. (2008) PEG-uricase in the management of treatment-resistant gout and hyperuricemia Adv. Drug Delivery Rev. 60, 59-68 (Pubitemid 350186186)
15. Cheng, T.-L., Wu, P.-Y., Wu, M.-F., Chern, J.-W., and Roffler, S. R. (1999) Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM Bioconjugate Chem. 10, 520-528 (Pubitemid 29243337)
16. Cheng, T.-L., Chen, B.-M., Chern, J.-W., Wu, M.-F., and Roffler, S. R. (2000) Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy Bioconjugate Chem. 11, 258-266 (Pubitemid 30174492)
17. Tsai, N., Cheng, T.-L., and Roffler, S. R. (2001) Sensitive measurement of polyethylene glycol-modified proteins BioTechniques 30, 396-402 (Pubitemid 32158566)
18. Cheng, T.-L., Cheng, C.-M., Chen, B.-M., Tsao, D.-A., Chuang, K.-H., Hsiao, S.-W., Lin, Y.-H., and Roffler, S. R. (2005) Monoclonal antibody-based quantitation of poly(ethylene glycol)-derivatized proteins, liposomes, and nanoparticles Bioconjugate Chem. 16, 1225-1231 (Pubitemid 41368125)
19. Roffler, S., Cheng, T.-L., and Wu, P.-Y., Academia Sinica, Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules. U.S. Patent No. 6,596,849 B1, Jul. 22, 2003.
20. Roffler, S., Cheng, T.-L., and Wu, P.-Y., Academia Sinica, Monoclonal antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules. U.S. Patent No. 6,617,118 B2, Sept. 9, 2003.
21. Roffler, S., Cheng, T.-L., and Wu, P.-Y., Academia Sinica, Monoclonal antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules. U.S. Patent No. 7,320,791 B2, Jan. 22, 2008.
22. Armstrong, J. K., Wenby, R. B., Meiselman, H. J., and Fisher, T. C. (2003) In vivo survival of poly(ethylene glycol)-coated red blood cells in the rabbit Blood 102, 94a
23. Garratty, G. (2008) Modulating the red cell membrane to produce universal/stealth donor red cells suitable for transfusion Vox Sang. 94, 87-95
24. Dams, E. T. M., Laverman, P., Oyen, W. J. G., Storm, G., Scherphof, G. L., Van Der Meer, J. W. M., Corstens, F. H. M., and Boerman, O. C. (2000) Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes J. Pharmacol. Exp. Ther. 292, 1071-1079 (Pubitemid 30136603)
25. Semple, S. C., Harasym, T. O., Clow, K. A., Ansell, S. M., Klimuk, S. K., and Hope, M. J. (2005) Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid J. Pharmacol. Exp. Ther. 312, 1020-1026 (Pubitemid 40293760)
26. Środa, K., Rydlewski, J., Langner, M., Kozubek, A., Grzybek, M., and Sikorski, A. F. (2005) Repeated injections of PEG-PE liposomes generate anti-PEG antibodies Cell. Mol. Biol. Lett. 10, 37-47 (Pubitemid 40559058)
27. Judge, A., McClintock, K., Phelps, J. R., and MacLachlan, I. (2006) Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes Mol. Ther. 13, 328-337 (Pubitemid 43056898)
28. Ishida, T., Wang, X. Y., Shimizu, T., Nawata, K., and Kiwada, H. (2007) PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner J. Controlled Release 122, 349-355 (Pubitemid 47407760)
29. Ishida, T., Kashima, S., and Kiwada, H. (2008) The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats J. Controlled Release 126, 162-165
30. Ganson, N. J., Kelly, S. J., Scarlett, E., Sundy, J. S., and Hershfield, M. S. (2006) Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase Arthritis Res. Ther. 8, R12
31. Sundy, J. S., Ganson, N. J., Kelly, S. J., Scarlett, E. L., Rehrig, C. D., Huang, W., and Hershfield, M. S. (2007) Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout Arthritis Rheum. 56, 1021-1028 (Pubitemid 46399452)
32. Hatfield, R. M., Morris, B. A., and Henry, R. R. (1987) Development of an enzyme linked immunosorbent assay for the detection of humoral antibody to Pasteurella anatipestifer Avian Pathology 16, 123-140
33. Kunitani, M., Dollinger, G., Johnson, D., and Kresin, L. (1991) On-line characterization of polyethylene glycol-modified proteins J. Chromatogr. 588, 125-137
34. Skoog, B. (1979) Determination of polyethylene glycols 4000 and 6000 in plasma protein preparations Vox Sang. 37, 345-349 (Pubitemid 10131371)
35. Porstmann, B., Porstmann, T., and Nugel, E. (1981) Comparison of chromogens for the determination of horseradish peroxidase as a marker in enzyme immunoassay J. Clin. Chem. Clin. Biochem. 19, 435-439 (Pubitemid 11085549)
36. 3H]thymidine incorporation assay J. Immunol. Methods 170, 211-224 (Pubitemid 24122510)
37. Evinger, M., Maeda, S., and Pestka, S. (1981) Recombinant human leukocyte interferon produced in bacteria has antiproliferative activity J. Biol. Chem. 256, 2113-2114 (Pubitemid 11151466)
38. Bekisz, J., Baron, S., Balinsky, C., Morrow, A., and Zoon, K. C. (2010) Antiproliferative properties of Type I and Type II interferon Pharmaceuticals (Basel) 3, 994-1015
39. Kitamura, T., Tange, T., Terasawa, T., Chiba, S., Kuwaki, T., Miyagawa, K., Piao, Y.-F., Miyazono, K., Urabe, A., and Takaku, F. (1989) Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin J. Cell. Physiol. 140, 323-334 (Pubitemid 19185998)
40. Kitamura, T., Takaku, F., and Miyajima, A. (1991) IL-1 up-regulates the expression of cytokine receptors on a factor-dependent human hemopoietic cell line, TF-1 Int. Immunol. 3, 571-577
41. Behr-Gross, M.-E., Daas, A., Burns, C., and Bristow, A. F. (2007) Collaborative study for the establishment of erythropoietin BRP batch 3 Pharmeuropa Bio. 2007-1, 49-66
42. Curran, M. P. and McCormack, P. L. (2008) Methoxy polyethylene glycol-epoetin beta: A review of its use in the management of anaemia associated with chronic kidney disease Drugs 68, 1139-1156 (Pubitemid 351693680)
43. Wedekin, M., Ehrich, J. H. H., and Pape, L. (2011) Effective treatment of anemia in pediatric kidney transplant recipients with methoxy polyethylene glycol-epoetin beta Pediatr. Transplant. 15, 329-333
44. TM) in children with ALL: Drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols Br. J. Haematol. 110, 379-384 (Pubitemid 30646864)
45. Armstrong, J. K., Hempel, G., Koling, S., Chan, L. S., Fisher, T., Meiselman, H. J., and Garratty, G. (2007) Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients Cancer 110, 103-111 (Pubitemid 46986423)
46. Sundy, J. S., Becker, M. A., Baraf, H. S. B., Barkhuizen, A., Moreland, L. W., Huang, W., Waltrip, R. W., II, Maroli, A. N., and Horowitz, Z. (2008) Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout. Results of a Phase II randomized study Arthritis Rheum. 58, 2882-2891 for the Pegloticase Phase 2 Study Investigators.
47. Sundy, J. S., Baraf, H. S. B., Yood, R. A., Edwards, N. L., Gutierrez-Urena, S. R., Treadwell, E. L., Vázquez-Mellado, J., White, W. B., Lipsky, P. E., Horowitz, Z., Huang, W., Maroli, A. N., Waltrip, R. W., II, Hamburger, S. A., and Becker, M. A. (2011) Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: Two randomized controlled trials JAMA 306, 711-720
48. Foster, G. R. (2010) Pegylated interferons for the treatment of chronic hepatitis C: Pharmacological and clinical differences between peginterferon-α-2a and peginterferon-α-2b Drugs 70, 147-165
49. Yang, B. B. and Kido, A. (2011) Pharmacokinetics and pharmacodynamics of pegfilgrastim Clin. Pharmacokinet. 50, 295-306
50. Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., Schreiber, S., and for the PRECISE 1 Study Investigators. (2007) Certolizumab pegol for the treatment of Crohn's disease N. Engl. J. Med. 357, 228-238 (Pubitemid 47080387)
51. Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. Ø., Hanauer, S. B., McColm, J., Bloomfield, R., Sandborn, W. J., and for the PRECISE 2 Study Investigators. (2007) Maintenance therapy with certolizumab pegol for Crohn's disease N. Engl. J. Med. 357, 239-250 (Pubitemid 47080388)
52. Booth, C. and Gaspar, H. B. (2009) Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID) Biologics 3, 349-358
53. Trainer, P. J., Ezzat, S., D'Souza, G. A., Layton, G., and Strasburger, C. J. (2009) A randomized, controlled multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly Clin. Endocrinol. 71, 549-557
54. Silver Lake Research. Reagent Specification Sheet Catalog #: CH2074,Anti-PolyethyleneGlycol (PEG) Monoclonal Antibody.